Boston, MA 07/02/2014 (wallstreetpr) – Agenus Inc (NASDAQ:AGEN) announced that its experimental drug for brain cancer showed impressive results in mid-stage study. The treatment showed that patients lived almost twice as long compared with those under standard treatments.
In cases where patients only survive for less than a year under standard treatments, the experimental drug made the patients live for two years. The standard treatment involves the use of radiation and chemotherapy drugs. The experimental treatment also showed impressive results in suppressing the progression of the disease.
Agenus (NASDAQ:AGEN) has partnered with GlaxoSmithKline (GSK) for the development of its lead experimental drug for the treatment of melanoma, shingles and malaria. The company is also in a deal with Pfizer Inc (NYSE:PFE) for the testing of its lead drug candidate for treatment of Alzheimer’s disease.
Shares of Agenus (NASDAQ:AGEN) gained more than 10 percent on the bank of the encouraging results. The shares are up almost 34 percent since the beginning of 2014.
The lone analyst covering the newly publicly launched GoPro Inc (NASDAQ:GPRO) believe the stock still have significant room to rise. Charles Anderson of Dougherty & Co. is optimistic about the future of the stock both in terms of market opportunities and investor confidence. He planted a Buy rating on the stock and issued a price target of $28 before the Thursday IPO. The stock was offered at $24 per share in the IPO.
Shares of GoPro Inc (NASDAQ:GPRO) shot up more than 20 percent to hit $48.80 per share in the previous session.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has announced that its second Phase 3 trial for its experimental treatment, migalastat, will focus on testing the drug further as a monotherapy in the treatment of Fabry. The company reported impressive first Phase 3 study of the drug. The update on the further study of migalastat was followed by a positive rating from JPMorgan Chase & Co. (NYSE:JPM) that rated it Overweight with price target of $7. The majority of analysts covering the stock have recommended a Buy.
